



## **Cancer Prevention and Control CIRB Meeting Agenda**

**November 21, 2023**

---

### **I. Initial ReReview**

**WF-2202**, Optimizing Psychosocial Intervention for Breast Cancer-related Sexual Morbidity: The Sexual Health and Intimacy Education (SHINE) Trial (Version Date 11/01/23)

---

### **II. Initial ReReview**

**EAQ223**, The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials (Version Date 11/13/23)

---

### **III. Amendment Review**

**MDA20-02-01**, Time Restricted Eating And Metformin (TEAM) in Invasive Breast Cancer (IBC) or Ductal Carcinoma in Situ (DCIS). A randomized, Phase IIb, Window of Opportunity Presurgical Trial. (Version Date 10/31/23)

---

### **IV. Continuing Review**

**A171601**, A phase II trial assessing the tolerability of palbociclib in combination with letrozole or fulvestrant in patients aged 70 and older with estrogen receptor-positive, HER2-negative metastatic breast cancer (Version Date 05/29/20)

---

**V. Continuing Review**

**A221805**, Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study (Version Date 01/20/23)

---

**VI. Continuing Review**

**S1600**, A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes (SIMmune) (Version Date 11/09/21)

---

**VII. Continuing Review**

**UAZ21-07-01**, M4OC-Prevent 2.0: Phase IIb Trial of Metformin for Oral Cancer Prevention (Version Date 03/28/23)

---